Skip to main content

OptimizeRx Corp

For the period ended Jun 9, 2026. Filed Apr 30, 2026.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Jun 9, 2026 · Filed Apr 30, 2026

OPRX$8.76+1.0%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

APPENDIX A

NON-GAAP FINANCIAL MEASURES

This proxy statement includes certain references to Adjusted EBITDA, which is a financial measure not derived in accordance with generally accepted accounting principles (GAAP). This non-GAAP financial measure is a measure of performance not defined by accounting principles generally accepted in the United States and should be considered in addition to, not in lieu of, GAAP reported measures. Additionally, this non-GAAP measure may not be comparable to similarly titled measures reported by other companies. However, management believes that presenting certain non-GAAP financial measures provides additional information to facilitate comparison of the Company’s historical operating results and trends in its underlying operating results and provides transparency on how the Company evaluates its business. Management uses this non-GAAP financial measure in making financial, operating and planning decisions and in evaluating the Company’s performance. Management believes that financial information excluding certain items that are not considered to reflect the Company’s ongoing operating results, such as the measure listed below, improves the comparability of year-to-year results. Consequently, management believes that investors may be able to better understand the Company’s operating results excluding these items. Non-GAAP financial measures may reflect adjustments for items such as asset impairment charges, amortization, stock-based compensation, acquisition expenses, severance, deferred income taxes, as well as other items that management believes are not related to the Company’s ongoing performance.

For the Twelve Months Ended December 31, 2025

($ in thousands)

Net income5,132
Depreciation and amortization4,327
Stock-based compensation6,962
Impairment charges368
Severance charges275
Shareholder activist related fees451
CEO search fees225
Other income(198)
Interest expense (income), net4,941
Income tax expense (benefit)1,818
Adjusted EBITDA (as reported)24,301
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.